Analysis of the Recurrence of Plus Disease after Intravitreal Ranibizumab as a Primary Monotherapy for Severe Retinopathy of Prematurity.

Journal: Ophthalmology. Retina
Published Date: Jan 3, 2018

Abstract

PURPOSE: To assess the outcomes of severe retinopathy of prematurity (ROP) in zone I or posterior zone II, and of aggressive posterior ROP treated with a single dose of intravitreal ranibizumab (IVR) as monotherapy.

Authors

  • Odalis Arámbulo
    Department of Ophthalmology, University Hospital of Maracaibo, Maracaibo, Venezuela.
  • Gabriel Dib
    Department of Ophthalmology, University Hospital of Maracaibo, Maracaibo, Venezuela.
  • Juan Iturralde
    Department of Ophthalmology, University Hospital of Maracaibo, Maracaibo, Venezuela.
  • Miguel Brito
    Department of Ophthalmology, University Hospital of Maracaibo, Maracaibo, Venezuela.
  • João B Fortes Filho
    Department of Ophthalmology, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: joaoborgesfortes@gmail.com.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals